九州通品牌怎么样 申请店铺

我要投票 九州通在减肥药行业中的票数:874 更新时间:2026-01-23
九州通是哪个国家的品牌?「九州通」是 九州通医药集团股份有限公司 旗下著名品牌。该品牌发源于湖北,由创始人刘宝林在2000期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力九州通品牌出海!将品牌入驻外推网,定制九州通品牌推广信息,可以显著提高九州通产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

九州通怎么样

九州通医药集团股份有限公司是一家以药品、医疗器械、生物制品、保健品等产品批发、零售连锁、药品生产与研发及有关增值服务为核心业务的大型企业集团。

截至2012年12月31日,九州通医药集团拥有总资产148.04亿元,员工9,148人,下属公司80余家,直营和加盟的零售连锁药店875家。2012年,九州通医药集团实现营业收入295.08亿元,上缴税收近5亿元。

九州通医药集团拥有完善的品种结构和丰富的客户资源,经营品规达160,000多个,上游供货商5,600家,下游客户70,000多家,取得了国内131种药品的全国或区域总经销或总代理资格。至今为止,九州通医药集团已在全国22个省会城市设立了22家省级子公司(大型医药物流中心)、在29个地级市设立了29家地级公司(地区医药物流配送中心)及400多个终端配送点,形成了覆盖全国大部分县级行政区域的物流配送网络。

打造企业核心竞争力,九州通医药集团秉持“技术让服务更卓越”的理念,致力于现代物流技术和信息技术的开发和应用。目前,九州通医药集团是国内唯一具备独立整合物流规划、物流实施、系统集成能力的医药分销企业,并取得了20多项自主知识产权,在现代物流技术和信息技术方面处于国内领先、国际一流的地位,是国内医药行业唯一获得“中国物流改革开放30年旗帜企业”称号的企业。

九州通医药集团具备向上下游客户提供需求解决方案及增值服务的能力,并逐渐将技术增值服务延伸到了上下游产业链,形成了独具特色的物流管理、供应链管理、医院管理三大产品线,可以满足客户对技术的最高要求。

近年来,九州通医药集团曾获得“国家5A级物流企业”、“湖北省最具影响力民营企业”、“湖北省守合同重信用企业”、“中国社会责任感优秀企业”、“全国非公有制企业双强百佳党组织”等多项荣誉。

未来,九州通医药集团将顺应医药市场变革,继续坚持以医药分销为核心业务,以医院纯销、中药材、医疗器械、零售连锁为战略业务,以物流技术营销、电子商务、国际贸易、原料药等为新兴业务的业务组合战略;扩大和完善医药营销网络布局,不断为医药健康产业提供高性价比服务,努力将九州通打造成为中国医药健康产业最佳服务商。

JIUZHOUTONG Pharmaceutical Group Co., Ltd. is a large-scale enterprise group with the core business of wholesale, retail chain, drug production and R & D and related value-added services of drugs, medical devices, biological products, health products and other products. As of December 31, 2012, JIUZHOUTONG Pharmaceutical Group has a total assets of 14.804 billion yuan, 9148 employees, more than 80 subordinate companies, 875 retail chain drugstores directly operated and joined. In 2012, JIUZHOUTONG Pharmaceutical Group achieved an operating revenue of 29.508 billion yuan and turned in tax revenue of nearly 500 million yuan. JIUZHOUTONG Pharmaceutical Group has a complete variety structure and rich customer resources. It operates more than 160000 products, 5600 upstream suppliers and 70000 downstream customers. It has obtained the qualification of national or regional general distribution or general agent of 131 kinds of drugs in China. So far, JIUZHOUTONG Pharmaceutical Group has set up 22 provincial subsidiaries (large pharmaceutical logistics centers) in 22 provincial capitals, 29 prefecture level companies (regional pharmaceutical logistics distribution centers) and more than 400 terminal distribution points in 29 prefecture level cities, forming a logistics distribution network covering most county-level administrative regions of the country. To build the core competitiveness of the enterprise, JIUZHOUTONG Pharmaceutical Group adheres to the concept of "technology makes service more excellent", and is committed to the development and application of modern logistics technology and information technology. At present, JIUZHOUTONG Pharmaceutical Group is the only pharmaceutical distribution enterprise in China that has the ability to independently integrate logistics planning, logistics implementation and system integration, and has obtained more than 20 independent intellectual property rights. It is in the leading position in modern logistics technology and information technology in China and the first-class position in the world. It is the only one in the domestic pharmaceutical industry that has won the title of "30 years banner enterprise of China's logistics reform and opening up" Enterprises. JIUZHOUTONG Pharmaceutical Group has the ability to provide demand solutions and value-added services to upstream and downstream customers, and gradually extends technology value-added services to the upstream and downstream industrial chains, forming a unique logistics management, supply chain management, hospital management three product lines, which can meet the highest requirements of customers for technology. In recent years, JIUZHOUTONG Pharmaceutical Group has won many honors, such as "national 5A level logistics enterprise", "the most influential private enterprise in Hubei Province", "Hubei Province contract abiding and trustworthy enterprise", "China's outstanding enterprise of social responsibility", "national top 100 Party organizations of non-public enterprises". In the future, JIUZHOUTONG Pharmaceutical Group will continue to adhere to the core business of pharmaceutical distribution, the strategic business of hospital pure sales, Chinese herbal medicine, medical devices, retail chain, the business combination strategy of logistics technology marketing, e-commerce, international trade, API and other emerging businesses, expand and improve the layout of pharmaceutical marketing network, and continue to serve the medical health The industry provides cost-effective services and strives to build Jiuzhoutong into the best service provider in China's pharmaceutical and health industry.

本文链接: https://brand.waitui.com/02808d9a5.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

美股大型科技股盘前涨跌不一,Arm涨超2%

36氪获悉,美股大型科技股盘前涨跌不一,截至发稿,Arm涨超2%,英伟达涨超1%,谷歌涨0.1%,微软涨0.06%;特斯拉跌0.17%,奈飞跌0.11%,亚马逊跌0.07%,苹果跌0.03%。

2小时前

热门中概股美股盘前涨跌互现,阿里巴巴跌超1%

36氪获悉,热门中概股美股盘前涨跌互现,截至发稿,阿里巴巴、京东跌超1%,小鹏汽车跌近1%,网易跌0.48%,蔚来跌0.21%;百度涨超1%,拼多多涨0.75%,理想汽车涨0.42%,B站涨0.09%。

2小时前

晶升股份:拟购买为准智能100%股份,交易作价8.57亿元

36氪获悉,晶升股份公告,公司拟通过发行股份及支付现金的方式购买本尚科技等10名交易对方持有的为准智能100%股份,同时募集配套资金。为准智能100%股份的交易作价为8.57亿元。本次交易构成关联交易和重大资产重组,但不构成重组上市。交易完成后,为准智能将成为上市公司控股子公司。

2小时前

天合光能:将剩余募集资金17亿元用于新项目“分布式智慧光伏电站建设项目”

36氪获悉,天合光能公告,公司拟缩减“年产35GW直拉单晶项目”的募集资金投资金额,不再实施二期15GW项目,并将剩余募集资金17亿元用于新项目“分布式智慧光伏电站建设项目”。新项目预计2026年底建成并投入运营。公司表示,本次变更有利于提高募集资金使用效率,合理优化资源配置,巩固市场地位,不会对公司正常经营产生不利影响。该事项尚需提交公司股东会和债券持有人会议审议通过后方可实施。

2小时前

宝洁第二财季净销售额222亿美元,同比增长1%

当地时间1月22日,宝洁公司发布2026财年第二季度(2025年10-12月)财报。财报显示,第二财季净销售额为222亿美元,同比增长1%;摊薄后每股净收益为1.78美元,同比下降5%。该公司维持2026财年总销售额同比增长1%至5%的指引区间,将2026财年摊薄后每股净收益增长指引从原先的3%-9%调整至1%-6%。(界面)

2小时前

本页详细列出关于九州通的品牌信息,含品牌所属公司介绍,九州通所处行业的品牌地位及优势。
咨询